Table 1.
The role of CMA in different cancers.
Type of Cancer | CMA Action Factor and Its Activity |
CMA Activity | Cellular Physiological Processes | Subjects | Cancer Development |
Reference |
---|---|---|---|---|---|---|
Pancreatic carcinoma | IGF-IR, Down | Up | Cell signaling | The human PC Cell lines | Inhibition | [73] |
Ovarian carcinoma | HK2, Down | Up | Glucose metabolism | Cell lines | Inhibition | [48] |
Breast carcinoma | HSD17B4, Down | Up | Protein modification | Breast cancer tissues | Inhibition | [52] |
ATG5, Down | Up | Gene transcription | Breast cancer Cell lines | Promotion | [70] | |
Hepatocellular carcinoma |
HMGB1, Down | Up | Gene expression | Cell lines | Promotion | [74] |
TP53, Down | Up | Gene expression | Cell lines | Inhibition | [49] | |
Colorectal carcinoma | P21, Down | Up | Gene expression | CRC tissues | Promotion | [65] |
Gastric carcinoma | RND3, Down | Up | Cell growth | GC tissues | Promotion | [64] |
Papillary thyroid carcinoma |
PPAR γ, Down | Up | Cell signaling | PTC tissues | Promotion | [72] |
Glioblastoma | N-CoR, Down | Up | Protein modification | Glioma cell line U87-MG and tissues | Promotion | [60] |
Lung carcinoma | N-CoR, Down | Up | Protein folding | Lung cancer cell lines | Promotion | [59] |
ErK3, Down | Up | Protein modification | Cell lines | Inhibition | [75] | |
MCL1, Up | Down | Protein modification | NSCLC cell lines | Promotion | [56] | |
Renal carcinoma | PKM2, Up | Down | Glucose metabolism | Cell lines | Promotion | [68] |
Prostate carcinoma | TPD52, Up | Down | Protein modification | C57BL/6 mouse | Promotion | [76] |